Skip to:


Official news and announcements about our company and our products.

Great news for RNA-based cancer vaccines

Very nice data from Sahin et al (Nature, 2017), showing that neo-epitope vaccination works in human subjects with melanoma.

The authors sequenced RNA from tumor biopsies to identify mutations that could serve as HLA-binding neo-epitopes. The resulting RNA-based vaccines were subsequently injected into a lymph node of the patient, and the idea is that dendritic cells will engulf the vaccine, translate the RNA-encoded antigens and present them to T cells.

The immunogenicity of the mutations was analysed by IFN-γ ELISpot pre- as well as post-vaccination. The promising post-vaccination results suggest that these kinds of patient-tailored vaccines may prevent recurrent disease in high risk patients, especially in combination with check-point blockade.

A very interesting bonus-finding was that a single mutation may give rise to neo-epitopes presented on different HLA class I molecules to different CD8+ T cell clones.

To find other references for Mabtech’s human IFN-γ ELISpot kits, please visit our Citations Database.

Friday, July 7, 2017

Launch of Bovine IgG ELISpot

With our new Bovine IgG ELISpot kit, you will be able to quantify the number of antibody producing plasma cells from cow. Antibodies are available as separate reagents.

The new kit and antibodies can be found in our webshop.

Thursday, July 6, 2017

Finally an ELISAPRO for Human TNF-ɑ

Human TNF-ɑ ELISAPRO kits for sensitive quantification of TNF-ɑ in serum, plasma and cell culture supernatants are now available in the web shop.

Our ELISAPRO kits are carefully validated complete kits including pre-coated strip-plates, reagents and buffers.

Thursday, July 6, 2017

Re-launch of mAb pair for llama IFN-γ

We are re-introducing the antibody clones PAN and bIFNγ-I after having confirmed good reactivity with llama IFN-γ.

The antibodies are available as separate reagents now, and complete ELISA and ELISpot kits will follow. 

Monday, July 3, 2017

Allogeneic dendritic cells as off-the-shelf immune boosters

Sweden-based Laurell et al (2017) think outside the box when they utilize allogeneic instead of autologous dendritic cells (DC) to enhance anti-tumor responses. These activated DCs are not used for antigen-presentation, but when injected into the tumor site they start a local inflammation and secrete pro-inflammatory cytokines and chemokines that attract and activate bystander autologous DCs. The autologous DCs will in turn engulf tumor debris, migrate to the draining lymph node and present tumor antigens to T cells.

Thus, this strategy uses the patient’s own tumor as antigen source in situ (double italics on that one!), circumventing the ordeal with producing tumor-antigen presenting autologous DCs in vitro. In addition, since there’s no MHC-restriction to account for, the allogenic DCs can act as an off-the-shelf immunogenic adjuvant for anti-tumor responses. Very cool.

Oh yeah, and of course the authors used Mabtech’s IFN-gamma ELISpotPLUS kit to evaluate tumor specific responses after putting their DC-based immunotherapy apporach to the test in patients with renal cell carcinoma.

Wednesday, June 28, 2017

B cell assays for pig samples

We have a totally new system to detect pig IgG. Choose between measuring antibody concentration with an ELISA, or enumerating antibody producing plasma cells using an ELISpot kit. The detection antibody for ELISA is available directly conjugated to HRP.

Please find all new kits and regents in the web shop.

Wednesday, June 28, 2017

iPSC-derived hepatocytes for drug identification and to study cellular pathophysiology

Cayo et al. have made an impressive work using new techniques such as iPSCs and humanized mice, to show that cardiac glycosides reduces hepatocyte production of apoB. They use apoB ELISA from Mabtech to analyze apoB secreted from iPSC-derived hepatocytes, and apoB in serum of avatar mice. They have also used the anti-apoB LDL17/20 for immunoprecipitation and Western Blot. Their article was published in April 2017 in the renowned journal Cell Stem Cell, and in the same edition, two other publications, Pashos et al. and Warren et al., are also analyzing secreted apoB from iPSC-derived hepatocytes using Mabtech’s apoB ELISA.

Liu et al. and Yang et al. are two additional recent papers studying inherited disorders with iPSC-derived hepatocytes, and like in the other articles, the authors are also using Mabtech’s apoB ELISA.

Friday, June 16, 2017

Use of R848 and IL-2 to stimulate memory B cells

In 2013, Jahnmatz, M et al published a newly developed protocol for polyclonal activation of human memory B cells. The authors showed the superior functionality of stimulating B cells using the TLR7/8-agonist R848 and IL-2 compared to the other stimulation protocols used at the time. Since then, we include R848 and IL-2 in all of our human immunoglobulin ELISpot and FluoroSpot kits.

The article is now one of the most highly cited papers in Journal of Immunological Methods.

Thursday, June 15, 2017

Characterization of Wilms’ tumor specific T cells with FluoroSpot

Danielzik et al. utilized Mabtech’s IFN-γ/Granzyme B FluroSpot kit to detect among others rare, specific, and double secreting T cells against Wilms’ tumor. The study honors high sensitivity, small sample size and the possibility to detect three different cell subsets in one FluoroSpot assay!

Tuesday, June 13, 2017

Mouse IgM Product Update

We are replacing our mouse IgM system with a newly developed monoclonal antibody pair from immunized rats. The improved antibodies are available in ELISA as well as ELISpot kits. In addition, we are for the first time introducing an ELISA with the detection antibody directly conjugated to enzyme HRP. Please find the new products in our web shop.

Thursday, June 8, 2017